{"transactions":[{"id":695331,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T20:22:26.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":240,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (\"Galera\") effected on July 12, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (\"Galera\") effected on July 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the \"Merger Agreement\"), by and among Galera, Obsidian Therapeutics, Inc. (\"Obsidian\"), Gazelle Parent, Inc. (\"Parent\"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (\"Obsidian Merger Sub\"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Galera Merger Sub\"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the \"Galera Merger\"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the \"Mergers\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an \"In-the-Money Option\"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the \"Merger Agreement\"), by and among Galera, Obsidian Therapeutics, Inc. (\"Obsidian\"), Gazelle Parent, Inc. (\"Parent\"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (\"Obsidian Merger Sub\"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Galera Merger Sub\"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the \"Galera Merger\"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the \"Mergers\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an \"In-the-Money Option\"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (\"Galera\") effected on July 12, 2026."}],"balance_after":0,"derivative":{"exercise_price":8.2,"expiration_date":"2035-02-23","underlying":"Common Stock","underlying_shares":240},"source":{"system":"sec-edgar","filing":"0001193125-26-335215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000119312526335215/ownership.xml","form_type":"4"}},{"id":695330,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-05T20:22:26.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40,"ownership":{"direct":false,"nature":"By the Lawrence M. Alleva Revocable Trust."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (\"Galera\") effected on July 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the \"Merger Agreement\"), by and among Galera, Obsidian Therapeutics, Inc. (\"Obsidian\"), Gazelle Parent, Inc. (\"Parent\"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (\"Obsidian Merger Sub\"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Galera Merger Sub\"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the \"Galera Merger\"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the \"Mergers\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Galera Merger (the \"Galera Effective Time\"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the \"Galera Exchange Ratio\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-335215","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000119312526335215/ownership.xml","form_type":"4"}},{"id":695329,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-05T20:22:26.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (\"Galera\") effected on July 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the \"Merger Agreement\"), by and among Galera, Obsidian Therapeutics, Inc. (\"Obsidian\"), Gazelle Parent, Inc. (\"Parent\"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (\"Obsidian Merger Sub\"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Galera Merger Sub\"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the \"Galera Merger\"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the \"Mergers\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Galera Merger (the \"Galera Effective Time\"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the \"Galera Exchange Ratio\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-335215","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000119312526335215/ownership.xml","form_type":"4"}},{"id":747797,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T23:03:50.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":2096,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":13336,"source":{"system":"sec-edgar","filing":"0001553053-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000155305326000002/primarydocument.xml","form_type":"4"}},{"id":946433,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":35,"underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946432,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":45.75,"underlying":"Common Stock","underlying_shares":384},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946431,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":358,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":49.25,"underlying":"Common Stock","underlying_shares":358},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946430,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946429,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":159,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":110.5,"underlying":"Common Stock","underlying_shares":159},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946428,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":310,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":56.75,"underlying":"Common Stock","underlying_shares":310},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946427,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":561,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":31.5,"underlying":"Common Stock","underlying_shares":561},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946426,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":215,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":85.5,"underlying":"Common Stock","underlying_shares":215},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946425,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":216,"underlying":"Common Stock","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946424,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":181,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":106.25,"underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946423,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":90.5,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946422,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":546,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":161,"underlying":"Common Stock","underlying_shares":546},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946421,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":372.5,"underlying":"Common Stock","underlying_shares":1002},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946420,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":527.25,"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946419,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":572.5,"underlying":"Common Stock","underlying_shares":368},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946418,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":134,"underlying":"Common Stock","underlying_shares":450},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946417,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":107.75,"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946416,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":107.75,"underlying":"Common Stock","underlying_shares":544},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946415,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":306.75,"underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946414,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":142,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":434.75,"underlying":"Common Stock","underlying_shares":142},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946413,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":437.5,"underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946412,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2460,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":9.0775,"underlying":"Common Stock","underlying_shares":2460},"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946411,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities were held directly by the Lawrence M. Alleva Revocable Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":946410,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:48:18.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":578,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001377","document":"tm261736-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001377/tm261736-7_4seq1.xml","form_type":"4"}},{"id":1111483,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:15:12.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":61500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":61500,"derivative":{"exercise_price":0.36,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":61500},"source":{"system":"sec-edgar","filing":"0001104659-25-059463","document":"tm2517941-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925059463/tm2517941-6_4seq1.xml","form_type":"4"}},{"id":1121186,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T21:09:23.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":976,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":11240,"source":{"system":"sec-edgar","filing":"0001562180-25-004510","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218025004510/primarydocument.xml","form_type":"4"}},{"id":1242474,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T21:43:38.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of February 24, 2026 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.041,"expiration_date":"2035-02-23","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0000905148-25-000784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000090514825000784/form4.xml","form_type":"4"}},{"id":1314455,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:39:05.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":12521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash.  The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $14,750 for the quarter ended December 31, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":12521,"derivative":{"exercise_price":1.4,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":12521},"source":{"system":"sec-edgar","filing":"0001104659-25-000833","document":"tm251918-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925000833/tm251918-1_4seq1.xml","form_type":"4"}},{"id":1391846,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-04T00:08:43.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":9615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $14,750 for the quarter ended September 30, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":9615,"derivative":{"exercise_price":1.83,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":9615},"source":{"system":"sec-edgar","filing":"0001104659-24-106019","document":"tm2425581-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924106019/tm2425581-1_4seq1.xml","form_type":"4"}},{"id":1462833,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-02T20:25:55.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":8972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $14,750 for the quarter ended June 30, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":8972,"derivative":{"exercise_price":1.97,"expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":8972},"source":{"system":"sec-edgar","filing":"0001104659-24-077365","document":"tm2418758-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924077365/tm2418758-1_4seq1.xml","form_type":"4"}},{"id":1465508,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:01:32.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1213926,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1213926,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1213926},"source":{"system":"sec-edgar","filing":"0001104659-24-076890","document":"tm2418639d2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465924076890/tm2418639d2_4seq1.xml","form_type":"4"}},{"id":1481969,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T20:49:34.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.26,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-24-070892","document":"tm2417031-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924070892/tm2417031-1_4seq1.xml","form_type":"4"}},{"id":1488289,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T21:21:52.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":902,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":10264,"source":{"system":"sec-edgar","filing":"0001562180-24-004753","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218024004753/primarydocument.xml","form_type":"4"}},{"id":1549343,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T00:14:42.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":3996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $14,750 for the quarter ended March 31, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":3996,"derivative":{"exercise_price":4.42,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":3996},"source":{"system":"sec-edgar","filing":"0001104659-24-043261","document":"tm2410803-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924043261/tm2410803-1_4seq1.xml","form_type":"4"}},{"id":1687625,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:15:56.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":7763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash.  The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $14,750 for the quarter ended December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":7763,"derivative":{"exercise_price":2.27,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":7763},"source":{"system":"sec-edgar","filing":"0001104659-24-001365","document":"tm241899-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924001365/tm241899-4_4seq1.xml","form_type":"4"}},{"id":1725295,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T22:02:39.000Z","date":"2023-12-01","kind":"sale","planned":false,"acquired":false,"shares":680,"price":88.585,"value":60237.8,"ownership":{"direct":true},"balance_after":9362,"source":{"system":"sec-edgar","filing":"0001562180-23-008013","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218023008013/primarydocument.xml","form_type":"4"}},{"id":1765221,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-10-04T20:27:36.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":14047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $14,750 for the quarter ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":14047,"derivative":{"exercise_price":1.26,"expiration_date":"2033-10-01","underlying":"Common Stock","underlying_shares":14047},"source":{"system":"sec-edgar","filing":"0001104659-23-106833","document":"tm2327613-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923106833/tm2327613-2_4seq1.xml","form_type":"4"}},{"id":1833765,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-06T20:24:24.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":5391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash.  The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $14,750 for the quarter ended June 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":5391,"derivative":{"exercise_price":3.42,"expiration_date":"2033-07-02","underlying":"Common Stock","underlying_shares":5391},"source":{"system":"sec-edgar","filing":"0001104659-23-078753","document":"tm2320657-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923078753/tm2320657-5_4seq1.xml","form_type":"4"}},{"id":1835264,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T20:19:45.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":22762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded pursuant to the \"elective option\" provisions of the Issuer's non-employee director compensation program for the Reporting Person's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date."}],"balance_after":22762,"derivative":{"exercise_price":3.12,"expiration_date":"2033-06-30","underlying":"Common Stock","underlying_shares":22762},"source":{"system":"sec-edgar","filing":"0000950170-23-031637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000095017023031637/ownership.xml","form_type":"4"}},{"id":1839335,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-07-03T21:02:08.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":1077756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1077756,"derivative":{"exercise_price":0.16,"exercise_date":"2024-07-03","expiration_date":"2033-07-03","underlying":"Ordinary Shares","underlying_shares":1077756},"source":{"system":"sec-edgar","filing":"0001104659-23-077666","document":"tm2320409-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465923077666/tm2320409-3_4seq1.xml","form_type":"4"}},{"id":1846413,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:52:47.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":1087,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":10042,"source":{"system":"sec-edgar","filing":"0001562180-23-005456","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218023005456/primarydocument.xml","form_type":"4"}},{"id":1851512,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T20:15:09.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":48000,"derivative":{"exercise_price":3.27,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0000899243-23-015763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924323015763/doc4.xml","form_type":"4"}},{"id":1858665,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:14:47.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":18355,"derivative":{"exercise_price":8.64,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18355},"source":{"system":"sec-edgar","filing":"0001104659-23-070351","document":"tm2318463-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070351/tm2318463-2_4seq1.xml","form_type":"4"}},{"id":1858664,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:14:47.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  Each RSU represents the contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":14467,"source":{"system":"sec-edgar","filing":"0001104659-23-070351","document":"tm2318463-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070351/tm2318463-2_4seq1.xml","form_type":"4"}},{"id":1924925,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-05T21:14:06.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":4525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $14,750 for the quarter ended March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant"}],"balance_after":4525,"derivative":{"exercise_price":4.25,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":4525},"source":{"system":"sec-edgar","filing":"0001104659-23-042241","document":"tm2311858-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923042241/tm2311858-2_4seq1.xml","form_type":"4"}},{"id":2204428,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-20T10:05:21.000Z","date":"2022-07-18","kind":"gift","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 18, 2022, the Reporting Person transferred 4,000 shares of common stock to a family trust of which the Reporting Person is trustee. The Reporting Person's spouse is the sole beneficiary of the trust."}],"balance_after":2325,"source":{"system":"sec-edgar","filing":"0000899243-22-026391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924322026391/doc4.xml","form_type":"4"}},{"id":2216769,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-07-01T21:03:25.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":816067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":816067,"derivative":{"exercise_price":0.28,"exercise_date":"2023-07-01","expiration_date":"2032-07-01","underlying":"Ordinary Shares","underlying_shares":816067},"source":{"system":"sec-edgar","filing":"0001104659-22-076900","document":"tm2220260-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465922076900/tm2220260-6_4seq1.xml","form_type":"4"}},{"id":2222969,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T20:53:53.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":1299,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":8955,"source":{"system":"sec-edgar","filing":"0001562180-22-005325","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218022005325/primarydocument.xml","form_type":"4"}},{"id":2229548,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:05:54.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.48,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-022793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924322022793/doc4.xml","form_type":"4"}},{"id":2235844,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:21:50.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.62,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-22-070144","document":"tm2218135-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922070144/tm2218135-6_4seq1.xml","form_type":"4"}},{"id":2443720,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:04:17.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":13657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022."}],"balance_after":13657,"derivative":{"exercise_price":6.44,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":13657},"source":{"system":"sec-edgar","filing":"0001104659-22-001556","document":"tm221771-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922001556/tm221771-3_4seq1.xml","form_type":"4"}},{"id":2640517,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T22:15:28.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":8498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded pursuant to the \"elective option\" provisions of the Issuer's non-employee director compensation program for the Reporting Peron's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date."}],"balance_after":8498,"derivative":{"exercise_price":10.09,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":8498},"source":{"system":"sec-edgar","filing":"0000899243-21-027604","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924321027604/doc4.xml","form_type":"4"}},{"id":2643689,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-07-02T21:03:21.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":505918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":505918,"derivative":{"exercise_price":0.71,"exercise_date":"2022-07-01","expiration_date":"2031-07-01","underlying":"Ordinary Shares","underlying_shares":505918},"source":{"system":"sec-edgar","filing":"0001104659-21-088972","document":"tm2121284-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465921088972/tm2121284-6_4seq1.xml","form_type":"4"}},{"id":2653341,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-28T20:03:50.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":671,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":7656,"source":{"system":"sec-edgar","filing":"0001562180-21-004517","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218021004517/primarydocument.xml","form_type":"4"}},{"id":2662969,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T22:41:54.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":9888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 16, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":9888,"derivative":{"exercise_price":8.9,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":9888},"source":{"system":"sec-edgar","filing":"0000899243-21-024506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924321024506/doc4.xml","form_type":"4"}},{"id":2668161,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T22:03:35.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":25050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":25050,"derivative":{"exercise_price":14.9,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":25050},"source":{"system":"sec-edgar","filing":"0001104659-21-081610","document":"tm2119714-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921081610/tm2119714-5_4seq1.xml","form_type":"4"}},{"id":2683092,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T22:58:03.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":1035,"price":14.38,"value":14883.3,"ownership":{"direct":false,"nature":"Held by Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"In a Form 4 filed on June 3, 2020, the reporting person reported direct beneficial ownership of 1,085 shares of the Company's common stock. Such shares are held directly by the Lawrence M. Alleva Revocable Trust and the nature of the reporting person's interest in such shares is indirect."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by the Lawrence M. Alleva Revocable Trust."}],"balance_after":2120,"source":{"system":"sec-edgar","filing":"0001104659-21-076535","document":"tm2118511-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921076535/tm2118511-1_4seq1.xml","form_type":"4"}},{"id":2682440,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T21:22:01.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":4045,"price":8.5887,"value":34741.2915,"ownership":{"direct":false,"nature":"By the Lawrence M. Alleva Revocable Trust."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.587 to $8.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":4045,"source":{"system":"sec-edgar","filing":"0000899243-21-021824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924321021824/doc4.xml","form_type":"4"}},{"id":2682439,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2021-06-03T20:31:00.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":12600,"price":0.79,"value":9954.0,"ownership":{"direct":false,"nature":"Held by Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.79 per ordinary share is derived from the weighted average purchase price paid on June 1, 2021 of $4.745 per ADS divided by six."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs."}],"balance_after":12600,"source":{"system":"sec-edgar","filing":"0001104659-21-076401","document":"tm2118429-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465921076401/tm2118429-1_4seq1.xml","form_type":"4"}},{"id":2902194,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-21T00:00:24.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":3339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2021."}],"balance_after":3339,"derivative":{"exercise_price":21.09,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":3339},"source":{"system":"sec-edgar","filing":"0001104659-21-005941","document":"tm211948d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921005941/tm211948d1_4seq1.xml","form_type":"4"}},{"id":2977024,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-17T21:06:42.000Z","date":"2020-11-13","kind":"purchase","acquired":true,"shares":2325,"price":10.2242,"value":23771.265,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6325,"source":{"system":"sec-edgar","filing":"0000899243-20-031268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924320031268/doc4.xml","form_type":"4"}},{"id":3094864,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-07-01T21:09:27.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":197678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":197678,"derivative":{"exercise_price":1.67,"exercise_date":"2021-07-01","expiration_date":"2030-07-01","underlying":"Ordinary Shares","underlying_shares":197678},"source":{"system":"sec-edgar","filing":"0001104659-20-079789","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465920079789/a4.xml","form_type":"4"}},{"id":3097498,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-30T00:11:58.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2021 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":9200,"derivative":{"exercise_price":22.9,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001104659-20-078229","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920078229/a4.xml","form_type":"4"}},{"id":3106932,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-17T20:16:21.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":801,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":6985,"source":{"system":"sec-edgar","filing":"0001562180-20-004527","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218020004527/primarydocument.xml","form_type":"4"}},{"id":3112959,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2020-06-12T01:00:40.000Z","date":"2020-06-09","kind":"purchase","acquired":true,"shares":12900,"price":1.89,"value":24381.0,"ownership":{"direct":false,"nature":"Held by Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 12,900 ordinary shares reported in Column 4 and Column 5 are represented by 2,150 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $1.89 per ordinary share is derived from the purchase price paid on June 9, 2020 of $11.354 per ADS divided by six."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The 12,900 ordinary shares reported in Column 4 and Column 5 are represented by 2,150 ADSs."}],"balance_after":12900,"source":{"system":"sec-edgar","filing":"0001104659-20-072556","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465920072556/a4.xml","form_type":"4"}},{"id":3114372,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-10T21:18:36.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":9888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 9, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":9888,"derivative":{"exercise_price":9.31,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":9888},"source":{"system":"sec-edgar","filing":"0000899243-20-015975","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924320015975/doc4.xml","form_type":"4"}},{"id":3123845,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T21:30:37.000Z","date":"2020-06-01","kind":"purchase","acquired":true,"shares":700,"price":22.94,"value":16058.0,"ownership":{"direct":true},"balance_after":1085,"source":{"system":"sec-edgar","filing":"0001104659-20-069498","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920069498/a4.xml","form_type":"4"}},{"id":3123844,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T21:30:37.000Z","date":"2020-06-01","kind":"purchase","acquired":true,"shares":385,"price":22.97,"value":8843.45,"ownership":{"direct":true},"balance_after":385,"source":{"system":"sec-edgar","filing":"0001104659-20-069498","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920069498/a4.xml","form_type":"4"}},{"id":3139024,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-21T20:01:32.000Z","date":"2020-05-19","kind":"purchase","acquired":true,"shares":227,"price":107.951,"value":24504.877,"ownership":{"direct":true},"balance_after":6184,"source":{"system":"sec-edgar","filing":"0001562180-20-003825","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218020003825/primarydocument.xml","form_type":"4"}},{"id":3150735,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-05-13T23:22:24.000Z","date":"2020-05-11","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001562180-20-003591","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218020003591/primarydocument.xml","form_type":"4"}},{"id":3150734,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T23:22:24.000Z","date":"2020-05-11","kind":"exercise","acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5957,"source":{"system":"sec-edgar","filing":"0001562180-20-003591","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218020003591/primarydocument.xml","form_type":"4"}},{"id":3322773,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T21:37:17.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":11264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2020."}],"balance_after":11264,"derivative":{"exercise_price":5.36,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":11264},"source":{"system":"sec-edgar","filing":"0001104659-20-000910","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920000910/a4.xml","form_type":"4"}},{"id":3338313,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T21:05:41.000Z","date":"2019-12-13","kind":"purchase","acquired":true,"shares":4000,"price":9.7847,"value":39138.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.8773, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0000899243-19-029402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000089924319029402/doc4.xml","form_type":"4"}},{"id":3467359,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-07-03T21:00:32.000Z","date":"2019-07-02","kind":"grant","acquired":true,"shares":271209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":271209,"derivative":{"exercise_price":0.61,"exercise_date":"2020-07-02","expiration_date":"2029-07-02","underlying":"Ordinary Shares","underlying_shares":271209},"source":{"system":"sec-edgar","filing":"0001104659-19-039321","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465919039321/a4.xml","form_type":"4"}},{"id":3494088,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T20:36:00.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2020 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":25000,"derivative":{"exercise_price":4.31,"expiration_date":"2029-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-19-034799","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465919034799/a4.xml","form_type":"4"}},{"id":3506257,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T20:01:31.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":739,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company."}],"balance_after":4957,"source":{"system":"sec-edgar","filing":"0001562180-19-003192","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218019003192/primarydocument.xml","form_type":"4"}},{"id":3527592,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-05-14T20:06:02.000Z","date":"2019-05-12","kind":"exercise","acquired":false,"shares":1011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company.  Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company.  Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company.  Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1011},"source":{"system":"sec-edgar","filing":"0001562180-19-002790","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218019002790/primarydocument.xml","form_type":"4"}},{"id":3527591,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T20:06:02.000Z","date":"2019-05-12","kind":"exercise","acquired":true,"shares":1011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company.  Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant."}],"balance_after":4218,"source":{"system":"sec-edgar","filing":"0001562180-19-002790","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218019002790/primarydocument.xml","form_type":"4"}},{"id":3690625,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":7209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":46.89,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":7209},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690624,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":149.22,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690623,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":47.27,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690622,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":60.77,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690621,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":26.36,"expiration_date":"2024-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690620,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":46.22,"expiration_date":"2023-06-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690619,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":21428,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":6.615,"expiration_date":"2022-04-27","underlying":"Common Stock","underlying_shares":21428},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690618,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Restricted Stock Units","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":4052,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4052},"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3690617,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-22T09:55:16.000Z","date":"2019-01-22","kind":"other","acquired":false,"shares":29902,"price":75,"value":2242650.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation (\"Purchaser\") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales (\"Parent\"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation (\"TESARO\"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the \"Merger Agreement\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001123292-19-000161","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000161/edgar.xml","form_type":"4"}},{"id":3703859,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-04T21:00:55.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":13619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2019."}],"balance_after":13619,"derivative":{"exercise_price":4.31,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":13619},"source":{"system":"sec-edgar","filing":"0001104659-19-000776","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465919000776/a4.xml","form_type":"4"}},{"id":3724306,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2018-12-20T01:04:23.000Z","date":"2018-12-17","kind":"purchase","acquired":true,"shares":47280,"price":0.84,"value":39715.2,"ownership":{"direct":false,"nature":"Held by Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 47,280 ordinary shares reported in Column 4 and Column 5 are represented by 7,880 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.84 per ordinary share is derived from the purchase price paid on December 17, 2018 of $5.006 per ADS divided by six."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The 47,280 ordinary shares reported in Column 4 and Column 5 are represented by 7,880 ADSs."}],"balance_after":47280,"source":{"system":"sec-edgar","filing":"0001104659-18-073869","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465918073869/a4.xml","form_type":"4"}},{"id":3809793,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-09-21T20:01:15.000Z","date":"2018-09-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2019 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":10000,"derivative":{"exercise_price":12.27,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-18-058010","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465918058010/a4.xml","form_type":"4"}},{"id":3850746,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-08-07T20:24:32.000Z","date":"2018-08-07","kind":"exercise","acquired":false,"shares":2272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares is fully vested."}],"balance_after":0,"derivative":{"exercise_price":22,"expiration_date":"2020-01-25","underlying":"Common Stock","underlying_shares":2272},"source":{"system":"sec-edgar","filing":"0001562180-18-003502","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218018003502/primarydocument.xml","form_type":"4"}},{"id":3850745,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-08-07T20:24:32.000Z","date":"2018-08-07","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares is fully vested."}],"balance_after":0,"derivative":{"exercise_price":34.96,"expiration_date":"2020-05-22","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-18-003502","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218018003502/primarydocument.xml","form_type":"4"}},{"id":3850744,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-07T20:24:32.000Z","date":"2018-08-07","kind":"sale","acquired":false,"shares":1248,"price":110.37,"value":137741.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $110.30 to $110.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3207,"source":{"system":"sec-edgar","filing":"0001562180-18-003502","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218018003502/primarydocument.xml","form_type":"4"}},{"id":3850743,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-07T20:24:32.000Z","date":"2018-08-07","kind":"sale","acquired":false,"shares":6424,"price":109.81,"value":705419.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $109.29 to $110.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":4455,"source":{"system":"sec-edgar","filing":"0001562180-18-003502","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218018003502/primarydocument.xml","form_type":"4"}},{"id":3850742,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-07T20:24:32.000Z","date":"2018-08-07","kind":"exercise","acquired":true,"shares":3000,"price":34.96,"value":104880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":10879,"source":{"system":"sec-edgar","filing":"0001562180-18-003502","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218018003502/primarydocument.xml","form_type":"4"}},{"id":3850741,"issuer":{"id":531,"kind":"organization","name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","symbol":"BFAM"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-07T20:24:32.000Z","date":"2018-08-07","kind":"exercise","acquired":true,"shares":2272,"price":22,"value":49984.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":7879,"source":{"system":"sec-edgar","filing":"0001562180-18-003502","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437578/000156218018003502/primarydocument.xml","form_type":"4"}}],"next_cursor":"2018-08-07T20:24:32.000000Z,3850741"}